XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Revenues from Contracts with Customers
 3 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenues from Contracts with Customers

3. Revenues from Contracts with Customers

Net product sales in the Rx Segment consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally “free-on-board” destination when shipped domestically within the United States, and “free-on-board” shipping point when shipped internationally, consistent with contractual terms.

The Company generates Consumer Health Segment revenue from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, consistent with contractual terms and aligning with the transfer of control of the products. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from customers are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost, and are included in cost of sales.

​

Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company continually monitors these provisions and does not believe variances between actual and estimated amounts have or will be material.

​

Revenues by Segment. Net revenue disaggregated by segment for the three months ended September 30, 2023 and 2022 were as follows:

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

September 30, 

​

    

2023

    

2022

​

​

(In thousands)

Consolidated revenue:

​

​

  

 

​

  

Rx Segment

​

$

17,817

​

$

18,652

Consumer Health Segment

​

 

4,282

​

 

9,003

Total consolidated revenue

​

$

22,099

​

$

27,655

 

​

Revenues by Product Portfolio. Net revenue disaggregated by significant product portfolio in the Rx Segment for the three months ended September 30, 2023 and 2022 were as follows:

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

September 30, 

​

​

2023

    

2022

​

​

(In thousands)

Rx Segment:

​

​

​

​

​

​

ADHD Portfolio

​

$

15,128

​

$

11,585

Pediatric Portfolio

​

​

2,565

​

​

6,558

Other

​

​

124

​

​

509

Total Rx Segment revenue

​

$

17,817

​

$

18,652

 

​

Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio.

​

Revenues by Geographic location. The Company’s revenues are predominately within the United States, with insignificant sales in Canada.